RTP Mobile Logo
Oncology Grand Rounds Series: Part 2 — Gastrointestinal Cancers
Released August 2016

Video excerpts from the second in a series of 8 integrated symposia held at the 2016 ONS Annual Congress. Featuring perspectives from Dr Johanna C Bendell, Dr Philip A Philip, Ms Robin Sommers and Ms Amanda K Wagner. (Video Program)

CE Disclosures and Faculty Information

    This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of gastrointestinal (GI) cancers.

    Cancer of the colon and rectum is the fourth most frequently diagnosed cancer and the second most common cause of death among all neoplasms in the United States, accounting for approximately 8% of all cancer deaths. The recent rapid expansion of novel biomarkers, multigene signatures and molecular-targeted systemic agents has significantly refined the clinical algorithm such that individualized therapeutic approaches have become the standard, and over the past two decades a number of new pathways, receptors and molecular targets have been identified and linked to colorectal cancer (CRC) growth and progression. This enhanced understanding of the biology of the disease has led to the investigation and approval of several novel therapeutic approaches.

    Given the prevalent nature of the disease, extensive resources are allocated to CRC research and education. Interestingly, however, although individually less frequently encountered, the collection of “non-CRC” GI cancers account for more per annum deaths than those attributed to tumors of the colon and rectum combined. Importantly, among this collection of distinct tumors, two areas in particular — gastric and pancreatic cancer — have witnessed several recent advances that have already drastically altered current treatment considerations and approaches.

    Although these new options have been welcomed by all, they create a challenge for those members of the interdisciplinary treatment team who are required to learn about, explain and appropriately integrate them into standard clinical practice, particularly oncology nurses, who play an integral role in the successful delivery of systemic anticancer therapy and the preservation of patient physical and psychosocial well-being. These video proceedings from the second part of an 8-part integrated CNE curriculum originally held at the 2016 ONS Annual Congress feature discussions with leading GI investigators and their nursing counterparts regarding actual patient cases and recent clinical research findings affecting the optimal therapeutic and supportive care for each patient scenario.

    By providing information on the latest research developments in the context of expert perspectives, this CNE activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with GI cancers.


    • Apply existing and emerging research data to the therapeutic and supportive care of patients with metastatic CRC (mCRC), gastric cancer and pancreatic cancer.
    • Describe the clinical impact of and toxicities associated with the use of bevacizumab, EGFR inhibitors, regorafenib and TAS-102 for mCRC.
    • Appreciate the recent FDA approvals of ramucirumab, TAS-102 and MM-398, and develop effective strategies to integrate these agents into the management of GI cancers.
    • Develop an evidence-based algorithm for the prevention and amelioration of side effects associated with chemotherapeutic and biologic agents used in the management of mCRC.
    • Consider age, performance status and other clinical and logistical factors in the selection of systemic therapy for patients with locally advanced or metastatic pancreatic cancer.


    CNE credit is no longer available for this issue


    CNE credit is no longer available for this issue

    The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.

    CNE credit is no longer available for this issue

    This is a video CNE program.

    CNE credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Johanna C Bendell, MD
    Director, GI Oncology Research
    Associate Director, Drug Development Unit
    Sarah Cannon Research Institute
    Nashville, Tennessee

    No relevant conflicts of interest to disclose.

    Philip A Philip, MD, PhD
    Professor of Oncology and Medicine
    Director of GI and Neuroendocrine Tumors
    Vice President of Medical Affairs
    Karmanos Cancer Institute
    Wayne State University
    Detroit, Michigan

    Advisory Committee: bioTheranostics Inc, Caris Life Sciences, Celgene Corporation, EMD Serono Inc, Halozyme Therapeutics, Lexicon Pharmaceuticals Inc, Merrimack Pharmaceuticals Inc; Contracted Research: Acerta Pharma, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Incyte Corporation, Karyopharm Therapeutics, Lilly, Merck, Momenta Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc, Taiho Oncology Inc, XBiotech; Speakers Bureau: Amgen Inc, Celgene Corporation, Genentech BioOncology, Novartis Pharmaceuticals Corporation.

    Robin Sommers, DNP, ANP-BC, AOCNP
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    No relevant conflicts of interest to disclose.

    Amanda K Wagner, MS, ANP-BC, AOCNP
    Arthur G James Cancer Hospital and Richard J Solove Research Institute
    The Ohio State University Comprehensive Cancer Center
    Columbus, Ohio

    No relevant conflicts of interest to disclose.

    MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Agendia Inc, Amgen Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Lilly, Merrimack Pharmaceuticals Inc and Taiho Oncology Inc.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: August 2016
    Expiration date: August 2017

    There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):
Video segments: